About Huntington’s Disease (HD)

One of the defining symptoms of HD is chorea, which is characterized by abnormal, abrupt, irregular movements. As HD progresses, chorea can become more frequent and severe, negatively impacting quality of life. While there is no established treatment to delay onset or progression of HD, a product called valbenazine is being evaluated as a potential treatment for HD-associated chorea.

Valbenazine was approved by the United States Food and Drug Administration (FDA) in April 2017 for the treatment of adults with tardive dyskinesia (TD), under the trade name INGREZZA®. The use of valbenazine for the treatment of HD-associated chorea has not been approved by the FDA.